n
ndiphenylamin
discov
potent
select
inhibitor
studi
conduct
determin
relationship
seri
inhibitor
sever
compound
display
submicromolar
potenc
select
relat
protein
also
demonstr
comput
model
reveal
alloster
site
distinct
camp
bind
domain
share
epac
isoform
provid
theori
regard
subtyp
select
figur
structur
camp
ht
hit
design
n
ndiphenylamin
new
class
inhibitor
letter
pubsacsorgacsmedchemlett
intracellular
effect
cyclic
adenosin
monophosph
camp
mediat
intracellular
effector
protein
evolutionari
conserv
camp
bind
domain
cnbd
prior
discoveri
exchang
protein
directli
activ
camp
epac
campmedi
signal
event
believ
transduc
larg
protein
kinas
pka
discoveri
epac
chang
landscap
campsign
research
evid
continu
emerg
underscor
import
epac
complex
relationship
pka
upon
bind
camp
epac
protein
activ
ra
superfamili
small
gtpase
date
mani
studi
shown
physiolog
pathophysiolog
signific
epac
protein
involv
cancer
bacteri
viral
infect
energi
homeostasi
obes
well
cardiac
function
given
mammalian
epac
protein
exist
two
structur
homolog
function
nonredund
isoform
develop
isoform
select
epac
inhibitor
molecular
probe
potenti
therapeut
urgent
need
herein
report
design
synthesi
pharmacolog
character
molecular
dock
result
function
n
ndiphenylamin
potent
select
inhibitor
previou
highthroughput
screen
ht
campaign
led
discoveri
sever
valid
hit
specif
epac
inhibitori
activ
subsequ
follow
extens
medicin
chemistri
optim
among
identifi
hit
diarylsulfon
arylsulfonamid
scaffold
relat
figur
explor
elucid
activ
relationship
sar
describ
previou
work
herein
present
synthesi
biolog
activ
n
ndiphenylamin
structur
relat
ht
hit
figur
gener
approach
depict
figur
retain
mesityl
moieti
are
favor
hydrophob
fragment
epac
antagonist
identifi
previou
studi
incorpor
variou
electron
withdraw
donat
group
differ
substitut
pattern
bring
diphenyl
amin
use
explor
bring
electron
requir
optim
inhibitori
activ
select
end
onestep
synthet
strategi
base
amin
protocol
util
facil
entri
potenti
inhibitor
scheme
bring
fragment
chosen
base
previou
find
commerci
avail
coupl
capac
describ
protocol
demethyl
methoxi
reduct
nitro
group
achiev
util
standard
protocol
afford
respect
synthet
protocol
detail
character
data
report
support
inform
si
previous
describ
assay
util
fluoresc
cyclic
nucleotid
analogu
use
quantifi
test
ligand
capac
prevent
bind
bind
purifi
lead
dosedepend
increas
fluoresc
signal
revers
camp
antagonist
therefor
fluoresc
intens
use
quantifi
potenc
synthes
compound
ic
valu
tabl
previou
report
disclos
tabl
diphenylamin
abl
prevent
bind
provid
rational
investig
larger
number
analogu
therefor
dichloro
analogu
synthes
assess
promis
activ
similar
previous
report
compound
eg
deriv
ic
incorpor
methyl
bring
prove
benefici
shown
ic
incorpor
fluorin
bromin
trichlorotrifluoro
provid
littl
increas
activ
inclus
trifluoromethyl
result
activ
compound
exampl
demonstr
inhibit
ic
incorpor
singl
methyl
trifluoromethyl
ethyl
dimethyl
hydrophob
moieti
show
virtual
gain
inhibitori
activ
trifluoromethyl
deriv
deriv
display
promis
inhibitori
activ
ic
respect
incorpor
electron
donat
group
provid
gain
activ
base
obtain
sar
hydrophob
phenyl
ring
remain
essenti
inhibitori
activ
consist
previous
report
antagonist
sever
promis
compound
figur
screen
select
previous
describ
vitro
guanin
nucleotid
exchang
factor
gef
function
assay
use
assess
select
given
bind
assay
use
ht
format
tabl
figur
compound
display
measur
activ
dose
test
report
assay
effect
yet
display
low
micromolar
inhibitori
activ
howev
nonselect
epac
antagonist
display
inhibitori
activ
condit
tabl
figur
suggest
aforement
compound
repres
potent
highli
select
inhibitor
interestingli
compound
inhibit
gef
activ
extent
activ
ablat
figur
compound
vari
capac
prevent
bind
see
figur
figur
compound
led
decreas
bind
approxim
compound
prevent
roughli
bind
howev
four
compound
display
nearli
inhibitori
activ
function
assay
suggest
test
inhibitor
may
prevent
bind
also
promot
conform
decreas
gef
activ
gain
insight
regard
select
molecular
dock
studi
perform
use
schroding
drug
discoveri
suit
investig
predict
bind
mode
n
ndiphenylamin
scaffold
pdb
see
experiment
method
si
contain
conserv
camp
bind
domain
bind
camp
high
affin
cnbdb
figur
bind
camp
cnbdb
result
conform
chang
epac
expos
catalyt
region
respons
rap
activ
howev
addit
camp
bind
domain
cnbda
bind
camp
low
affin
requir
regul
camp
interestingli
report
autoinhibitori
structur
cnbda
cnbdb
orient
toward
form
interfac
block
camp
caviti
figur
lack
interfac
given
contain
cnbdb
therefor
conceiv
small
molecul
prevent
bind
camp
probe
use
describ
assay
bridg
cnbda
cnbdb
domain
would
promot
stabil
autoinhibitori
versu
activ
state
transit
known
highli
dynam
epac
interact
possibl
lack
interfac
idea
support
fact
origin
ht
hit
lose
inhibitori
activ
upon
delet
cnbda
addit
act
noncompetit
inhibitor
campmedi
gef
activ
produc
rightwardshift
camp
reduct
maximum
activ
see
si
figur
suggest
similar
scaffold
may
access
alloster
site
interfac
cnbda
cnbdb
noncompetitivealloster
inhibit
propos
previou
report
ligand
act
hing
region
cnbdb
rem
figur
howev
hing
region
highli
conserv
epac
sinc
compound
select
inhibit
reason
suggest
aforement
compound
interact
interfac
camp
bind
domain
protein
therefor
molecular
dock
cnbda
cnbdb
interfac
conduct
ligand
lowest
energi
pose
overlaid
figur
show
welldefin
bind
pocket
camp
bind
domain
zoom
view
figur
predict
key
interact
electron
rich
ring
ly
cnbda
hbond
interact
n
ndiphenylamin
backbon
amid
carbonyl
cnbdb
therefor
privileg
mesityl
fragment
bridg
gap
cnbda
cnbdb
presum
stabil
autoinhibit
state
bind
mode
possibl
provid
absenc
cnbda
fact
one
compound
dock
interfac
similar
result
indic
basic
structur
requir
predict
bind
pose
diphenylamin
scaffold
except
compound
abl
access
propos
alloster
site
due
size
consist
fact
compound
ineffect
prevent
bind
tabl
moreov
ligand
strong
electron
donat
group
consist
display
ic
valu
weaker
compound
test
given
dock
indic
n
ndiphenylamin
interact
amid
carbonyl
cnbdb
conceiv
disrupt
avid
predict
hbond
interact
due
properti
aromat
ring
summari
seri
n
ndiphenylamin
deriv
design
synthes
evalu
systemat
inhibitor
molecular
dock
use
provid
insight
potenti
bind
mode
specif
alloster
site
uniqu
identifi
predict
interact
use
ration
observ
sar
data
stimul
new
strategi
toward
inhibit
epac
protein
compound
display
substanti
activ
highli
homolog
exhibit
submicromolar
potenc
best
knowledg
compound
compar
potent
synthes
select
inhibitor
report
date
compound
decent
physicochem
profil
ie
avg
ligand
effici
avg
tpsa
avg
mw
avg
clogp
see
si
tabl
may
use
facilit
effort
uncov
isoformspecif
role
epac
protein
studi
improv
druglik
eg
lipophil
solubl
molecul
maintain
activityselect
current
underway
author
declar
compet
financi
interest
would
like
thank
dr
lawrenc
c
sower
jacob
theruvathu
depart
pharmacolog
dr
tianzhi
wang
nmr
core
facil
utmb
nmr
spectroscopi
assist
